Establishment of a novel diagnostic test algorithm for human T-cell leukemia virus type 1 infection with line immunoassay replacement of western blotting: a collaborative study for performance evaluation of diagnostic assays in Japan
Kazu Okuma,
Madoka Kuramitsu,
Toshihiro Niwa,
Tomokuni Taniguchi,
Yumiko Masaki,
Gohzoh Ueda,
Chieko Matsumoto,
Rieko Sobata,
Yasuko Sagara,
Hitomi Nakamura,
Masahiro Satake,
Kiyonori Miura,
Naoki Fuchi,
Hideaki Masuzaki,
Akihiko Okayama,
Kazumi Umeki,
Yoshihisa Yamano,
Tomoo Sato,
Masako Iwanaga,
Kaoru Uchimaru,
Makoto Nakashima,
Atae Utsunomiya,
Ryuji Kubota,
Kenji Ishitsuka,
Hiroo Hasegawa,
Daisuke Sasaki,
Ki-Ryang Koh,
Mai Taki,
Kisato Nosaka,
Masao Ogata,
Isao Naruse,
Noriaki Kaneko,
Sara Okajima,
Kenta Tezuka,
Emi Ikebe,
Sahoko Matsuoka,
Kazuo Itabashi,
Shigeru Saito,
Toshiki Watanabe,
Isao Hamaguchi
Affiliations
Kazu Okuma
Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases
Madoka Kuramitsu
Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases
Toshihiro Niwa
Research and Development Division, Fujirebio Inc.
Tomokuni Taniguchi
Protein Technology, Engineering 1, Sysmex Corporation
Yumiko Masaki
Roche Diagnostics K.K.
Gohzoh Ueda
Abbott Japan LLC
Chieko Matsumoto
Central Blood Institute, Blood Service Headquarters, Japanese Red Cross Society
Rieko Sobata
Central Blood Institute, Blood Service Headquarters, Japanese Red Cross Society
Yasuko Sagara
Department of Quality, Japanese Red Cross Kyushu Block Blood Center
Hitomi Nakamura
Department of Quality, Japanese Red Cross Kyushu Block Blood Center
Masahiro Satake
Central Blood Institute, Blood Service Headquarters, Japanese Red Cross Society
Kiyonori Miura
Department of Obstetrics and Gynecology, Nagasaki University Graduate School of Biomedical Sciences
Naoki Fuchi
Department of Obstetrics and Gynecology, Nagasaki University Graduate School of Biomedical Sciences
Hideaki Masuzaki
Department of Obstetrics and Gynecology, Nagasaki University Graduate School of Biomedical Sciences
Akihiko Okayama
Department of Rheumatology, Infectious Diseases and Laboratory Medicine, University of Miyazaki
Kazumi Umeki
Department of Rheumatology, Infectious Diseases and Laboratory Medicine, University of Miyazaki
Yoshihisa Yamano
Division of Neurology, Department of Internal Medicine, St. Marianna University School of Medicine
Tomoo Sato
Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine
Masako Iwanaga
Department of Clinical Epidemiology, Nagasaki University Graduate School of Biomedical Sciences
Kaoru Uchimaru
Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo
Makoto Nakashima
Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo
Atae Utsunomiya
Department of Hematology, Imamura General Hospital
Ryuji Kubota
Division of Neuroimmunology, Joint Research Center for Human Retrovirus Infection, Kagoshima University
Kenji Ishitsuka
Department of Hematology and Rheumatology, Kagoshima University
Hiroo Hasegawa
Department of Laboratory Medicine, Nagasaki University Hospital
Daisuke Sasaki
Department of Laboratory Medicine, Nagasaki University Hospital
Ki-Ryang Koh
Department of Hematology, Osaka General Hospital of West Japan Railway Company
Mai Taki
Rakuwakai Kyoto Medical Examination Center
Kisato Nosaka
Department of Hematology, Kumamoto University of Medicine
Masao Ogata
Department of Hematology, Oita University Hospital
Isao Naruse
Department of Infection and Immunology, SRL Inc.
Noriaki Kaneko
Department of Infection and Immunology, SRL Inc.
Sara Okajima
Department of Infection and Immunology, SRL Inc.
Kenta Tezuka
Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases
Emi Ikebe
Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases
Sahoko Matsuoka
Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases
Kazuo Itabashi
Department of Pediatrics, Showa University School of Medicine
Shigeru Saito
Department of Obstetrics and Gynecology, University of Toyama
Toshiki Watanabe
Department of Hematology and Oncology, Research Hospital, Institute of Medical Science, The University of Tokyo
Isao Hamaguchi
Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases
Abstract Background The reliable diagnosis of human T-cell leukemia virus type 1 (HTLV-1) infection is important, particularly as it can be vertically transmitted by breast feeding mothers to their infants. However, current diagnosis in Japan requires a confirmatory western blot (WB) test after screening/primary testing for HTLV-1 antibodies, but this test often gives indeterminate results. Thus, this collaborative study evaluated the reliability of diagnostic assays for HTLV-1 infection, including a WB-based one, along with line immunoassay (LIA) as an alternative to WB for confirmatory testing. Results Using peripheral blood samples from blood donors and pregnant women previously serologically screened and subjected to WB analysis, we analyzed the performances of 10 HTLV-1 antibody assay kits commercially available in Japan. No marked differences in the performances of eight of the screening kits were apparent. However, LIA determined most of the WB-indeterminate samples to be conclusively positive or negative (an 88.0% detection rate). When we also compared the sensitivity to HTLV-1 envelope gp21 with that of other antigens by LIA, the sensitivity to gp21 was the strongest. When we also compared the sensitivity to envelope gp46 by LIA with that of WB, LIA showed stronger sensitivity to gp46 than WB did. These findings indicate that LIA is an alternative confirmatory test to WB analysis without gp21. Therefore, we established a novel diagnostic test algorithm for HTLV-1 infection in Japan, including both the performance of a confirmatory test where LIA replaced WB on primary test-reactive samples and an additional decision based on a standardized nucleic acid detection step (polymerase chain reaction, PCR) on the confirmatory test-indeterminate samples. The final assessment of the clinical usefulness of this algorithm involved performing WB analysis, LIA, and/or PCR in parallel for confirmatory testing of known reactive samples serologically screened at clinical laboratories. Consequently, LIA followed by PCR (LIA/PCR), but neither WB/PCR nor PCR/LIA, was found to be the most reliable diagnostic algorithm. Conclusions Because the above results show that our novel algorithm is clinically useful, we propose that it is recommended for solving the aforementioned WB-associated reliability issues and for providing a more rapid and precise diagnosis of HTLV-1 infection.